Key result
Alfacalcidol is linked to improved central SBP but not endothelial function in Type II diabetic nephropathy.
Why the study?
Does alfacalcidol improve microvascular endothelial function, arterial stiffness, and blood pressure in patients with Type II Diabetic Nephropathy?
Population
60 patients with Type II Diabetic Nephropathy (n=28 in treatment group, n=32 in control group)
Comparison
Alfacalcidol 0.25 μg daily for six months vs Conventional treatment
Design
Cohort
Follow-up
six months
Authors
Loading...
Alfacalcidol showed no microvascular or stiffness benefit in DN; leaves open efficacy in randomized trials.
Cohort (n=60)
Does alfacalcidol improve microvascular endothelial function, arterial stiffness, and blood pressure in patients with Type II Diabetic Nephropathy?
p-value: p=0.027 for CSBP
Alfacalcidol may improve central systolic blood pressure in patients with diabetic nephropathy, particularly those with vitamin D deficiency, though it does not appear to affect microvascular endothelial function.
Munisamy et al. (2015) conducted a cohort in Type II Diabetic Nephropathy (n=60). Alfacalcidol vs. Conventional treatment was evaluated on Microvascular endothelial function, arterial stiffness, and blood pressure (p=0.027 for CSBP). Alfacalcidol exposure did not affect microvascular endothelial function but significantly improved central systolic blood pressure (P=0.027) in patients with Type II diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: